Company news

Cybin, Inc. news in 2026

Cybin, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

November 3, 2026

Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development

October 27, 2026

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

October 21, 2026

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

October 15, 2026

Helus Pharma to Host Investor Presentation on October 21, 2026

October 8, 2026

Helus Pharma Announces Completion of Legal Name Change

October 1, 2026

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

September 22, 2026

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

September 21, 2026

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

September 10, 2026

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

September 9, 2026

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

September 3, 2026

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

August 18, 2026

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

August 14, 2026

Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston

August 10, 2026

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

August 3, 2026

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

July 21, 2026

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

July 17, 2026

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

June 29, 2026

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

June 26, 2026

Helus Pharma(TM) Announces Closing of US$50 Million Underwritten Offering

June 25, 2026

Helus Pharma(TM) Announces US$50 Million Underwritten Offering

June 24, 2026

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference

June 11, 2026

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

June 1, 2026

Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

April 30, 2026

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

April 28, 2026

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

April 23, 2026

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

April 20, 2026

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

April 16, 2026

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

March 12, 2026

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

March 9, 2026

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

March 5, 2026

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

February 24, 2026

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

February 17, 2026

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

February 13, 2026

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

February 10, 2026

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq

January 5, 2026

Decks in 2026